-
2
-
-
33845329568
-
Markers and tissue resources for melanoma: Meeting report
-
Becker D, Mihm MC, Hewitt SM et al (2006) Markers and tissue resources for melanoma: Meeting report. Cancer Res 66: 10652-10657
-
(2006)
Cancer Res
, vol.66
, pp. 10652-10657
-
-
Becker, D.1
Mihm, M.C.2
Hewitt, S.M.3
-
4
-
-
83755196805
-
BRAF inhibitors and melanoma
-
Flaherty KT (2011) BRAF inhibitors and melanoma. Cancer J 17:505-511
-
(2011)
Cancer J
, vol.17
, pp. 505-511
-
-
Flaherty, K.T.1
-
5
-
-
74949143594
-
Final version of 2009 AJCC melanoma staging and classification
-
Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
-
(2009)
J Clin Oncol
, vol.27
, pp. 6199-6206
-
-
Balch, C.M.1
Gershenwald, J.E.2
Soong, S.J.3
-
6
-
-
79953897102
-
Cutaneous melanoma: A model to study cancer metastasis
-
Leong SP, Gershenwald JE, Soong SJ et al (2011) Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103:538-549
-
(2011)
J Surg Oncol
, vol.103
, pp. 538-549
-
-
Leong, S.P.1
Gershenwald, J.E.2
Soong, S.J.3
-
7
-
-
0020508749
-
Modulation of the metastatic capability in B16 melanoma by cell shape
-
Raz A, Ben-Ze'ev A (1983) Modulation of the metastatic capability in B16 melanoma by cell shape. Science 221:1307-1310
-
(1983)
Science
, vol.221
, pp. 1307-1310
-
-
Raz A Ben-Ze'ev, A.1
-
8
-
-
33751252276
-
Cancer metastasis: Building a framework
-
Gupta GP, Massague J (2006) Cancer metastasis: Building a framework. Cell 127:679-695
-
(2006)
Cell
, vol.127
, pp. 679-695
-
-
Gupta, G.P.1
Massague, J.2
-
9
-
-
80054686286
-
Tumor metastasis: Molecular insights and evolving paradigms
-
Valastyan S, Weinberg RA (2011) Tumor metastasis: Molecular insights and evolving paradigms. Cell 147:275-292
-
(2011)
Cell
, vol.147
, pp. 275-292
-
-
Valastyan, S.1
Weinberg, R.A.2
-
10
-
-
83455171909
-
Betacatenin signaling controls metastasis in Braf-activated Ptendeficient melanomas
-
Damsky WE, Curley DP, Santhanakrishnan M et al (2011) betacatenin signaling controls metastasis in Braf-activated Ptendeficient melanomas. Cancer Cell 20:741-754
-
(2011)
Cancer Cell
, vol.20
, pp. 741-754
-
-
Damsky, W.E.1
Curley, D.P.2
Santhanakrishnan, M.3
-
11
-
-
0038481970
-
The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited
-
Fidler IJ (2003) The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 453-458
-
-
Fidler, I.J.1
-
12
-
-
0242456170
-
Axis of evil: Molecular mechanisms of cancer metastasis
-
Bogenrieder T, Herlyn M (2003) Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 22:6524-6536
-
(2003)
Oncogene
, vol.22
, pp. 6524-6536
-
-
Bogenrieder, T.1
Herlyn, M.2
-
13
-
-
0028841186
-
Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of beta 1 integrins
-
Mortarini R, Gismondi A, Maggioni A et al (1995) Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of beta 1 integrins. Cancer Res 55:4702-4710
-
(1995)
Cancer Res
, vol.55
, pp. 4702-4710
-
-
Mortarini, R.1
Gismondi, A.2
Maggioni, A.3
-
14
-
-
67650999875
-
The basics of epithelial-mesenchymal transition
-
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
-
(2009)
J Clin Invest
, vol.119
, pp. 1420-1428
-
-
Kalluri, R.1
Weinberg, R.A.2
-
15
-
-
80052964920
-
Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?
-
Scheel C, Weinberg RA (2011) Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129:2310-2314
-
(2011)
Int J Cancer
, vol.129
, pp. 2310-2314
-
-
Scheel, C.1
Weinberg, R.A.2
-
16
-
-
78649445049
-
Isolation of tumorigenic circulating melanoma cells
-
Ma J, Lin JY, Alloo A et al (2010) Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402:711-717
-
(2010)
Biochem Biophys Res Commun
, vol.402
, pp. 711-717
-
-
Ma, J.1
Lin, J.Y.2
Alloo, A.3
-
17
-
-
0346728596
-
Determinants of BRAF mutations in primary melanomas
-
Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 1878-1890
-
-
Maldonado, J.L.1
Fridlyand, J.2
Patel, H.3
-
18
-
-
33749021085
-
Somatic activation of KIT in distinct subtypes of melanoma
-
Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346
-
(2006)
J Clin Oncol
, vol.24
, pp. 4340-4346
-
-
Curtin, J.A.1
Busam, K.2
Pinkel, D.3
-
19
-
-
0027930910
-
Actin-binding protein expression in benign and malignant melanocytic proliferations
-
Bouffard D, Duncan LM, Howard CA et al (1994) Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol 25:709-714
-
(1994)
Hum Pathol
, vol.25
, pp. 709-714
-
-
Bouffard, D.1
Duncan, L.M.2
Howard, C.A.3
-
20
-
-
13044277567
-
Progression-related expression of beta3 integrin in melanomas and nevi
-
Van Belle PA, Elenitsas R, Satyamoorthy K et al (1999) Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30:562-567
-
(1999)
Hum Pathol
, vol.30
, pp. 562-567
-
-
Van Belle, P.A.1
Elenitsas, R.2
Satyamoorthy, K.3
-
21
-
-
22744438812
-
Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/ CD61): An important mechanism mediating melanoma cell adhesion to activated endothelium
-
Saalbach A, Wetzel A, Haustein UF et al (2005) Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/ CD61): An important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 24:4710-4720
-
(2005)
Oncogene
, vol.24
, pp. 4710-4720
-
-
Saalbach, A.1
Wetzel, A.2
Haustein, U.F.3
-
22
-
-
0032749387
-
Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression
-
Hofmann UB, Westphal JR, Waas ET et al (1999) Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 81:774-782
-
(1999)
Br J Cancer
, vol.81
, pp. 774-782
-
-
Hofmann, U.B.1
Westphal, J.R.2
Waas, E.T.3
-
23
-
-
0035087474
-
Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis
-
Bodey B, Bodey B Jr, Siegel SE et al (2001) Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis. In Vivo (Athens, Greece) 15:57-64
-
(2001)
Vivo (Athens, Greece
, vol.15
, pp. 57-64
-
-
Bodey, B.1
Bodey Jr., B.2
Siegel, S.E.3
-
24
-
-
84858793024
-
Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma
-
Chen Y, Huang L, Yu J (2012) Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol 39:339-343
-
(2012)
J Dermatol
, vol.39
, pp. 339-343
-
-
Chen, Y.1
Huang, L.2
Yu, J.3
-
25
-
-
84860273222
-
MDA-9/syntenin: A positive gatekeeper of melanoma metastasis
-
Das SK, Bhutia SK, Kegelman TP et al (2012) MDA-9/syntenin: A positive gatekeeper of melanoma metastasis. Front Biosci 17: 1-15
-
(2012)
Front Biosci
, vol.17
, pp. 1-15
-
-
Das, S.K.1
Bhutia, S.K.2
Kegelman, T.P.3
-
26
-
-
84862801153
-
Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway
-
Lu Z, Lu N, Li C et al (2012) Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209:211-220
-
(2012)
Toxicol Lett
, vol.209
, pp. 211-220
-
-
Lu, Z.1
Lu, N.2
Li, C.3
-
27
-
-
33745288277
-
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene
-
Kim M, Gans JD, Nogueira C et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281
-
(2006)
Cell
, vol.125
, pp. 1269-1281
-
-
Kim, M.1
Gans, J.D.2
Nogueira, C.3
-
28
-
-
84863230202
-
SOX2 contributes to melanoma cell invasion
-
Girouard SD, Laga AC, Mihm MC et al (2012) SOX2 contributes to melanoma cell invasion. Lab Investig 92:362-370
-
(2012)
Lab Investig
, vol.92
, pp. 362-370
-
-
Girouard, S.D.1
Laga, A.C.2
Mihm, M.C.3
-
29
-
-
79952724400
-
SOX2 and nestin expression in human melanoma: An immunohistochemical and experimental study
-
Laga AC, Zhan Q, Weishaupt C et al (2011) SOX2 and nestin expression in human melanoma: An immunohistochemical and experimental study. Exp Dermatol 20:339-345
-
(2011)
Exp Dermatol
, vol.20
, pp. 339-345
-
-
Laga, A.C.1
Zhan, Q.2
Weishaupt, C.3
-
30
-
-
76149092522
-
Expression of the embryonic stem cell transcription factor SOX2 in human skin: Relevance to melanocyte and merkel cell biology
-
Laga AC, Lai CY, Zhan Q et al (2010) Expression of the embryonic stem cell transcription factor SOX2 in human skin: Relevance to melanocyte and merkel cell biology. Am J Pathol 176:903-913
-
(2010)
Am J Pathol
, vol.176
, pp. 903-913
-
-
Laga, A.C.1
Lai, C.Y.2
Zhan, Q.3
-
31
-
-
0036163492
-
Melanoma-stroma interactions: Structural and functional aspects
-
Ruiter D, Bogenrieder T, Elder D et al (2002) Melanoma-stroma interactions: Structural and functional aspects. Lancet Oncol 3:35-43
-
(2002)
Lancet Oncol
, vol.3
, pp. 35-43
-
-
Ruiter, D.1
Bogenrieder, T.2
Elder, D.3
-
32
-
-
70350072797
-
Stromal expression of MMP-13 is required for melanoma invasion and metastasis
-
Zigrino P, Kuhn I, Bauerle T et al (2009) Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Investig Dermatol 129:2686-2693
-
(2009)
J Investig Dermatol
, vol.129
, pp. 2686-2693
-
-
Zigrino, P.1
Kuhn, I.2
Bauerle, T.3
-
33
-
-
12544253705
-
Malignant melanoma and HIV infection-aggressive course despite immune reconstitution
-
Hoffmann C, Horst HA, Weichenthal M et al (2005) Malignant melanoma and HIV infection-aggressive course despite immune reconstitution. Onkologie 28:35-37
-
(2005)
Onkologie
, vol.28
, pp. 35-37
-
-
Hoffmann, C.1
Horst, H.A.2
Weichenthal, M.3
-
34
-
-
79955562722
-
Prognostic geneexpression signature of carcinoma-associated fibroblasts in nonsmall cell lung cancer
-
Navab R, Strumpf D, Bandarchi B et al (2011) Prognostic geneexpression signature of carcinoma-associated fibroblasts in nonsmall cell lung cancer. Proc Natl Acad Sci USA 108:7160-7165
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 7160-7165
-
-
Navab, R.1
Strumpf, D.2
Bandarchi, B.3
-
35
-
-
72949083968
-
Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells
-
Navab R, Liu J, Seiden-Long I et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11:1292-1300
-
(2009)
Neoplasia
, vol.11
, pp. 1292-1300
-
-
Navab, R.1
Liu, J.2
Seiden-Long, I.3
-
36
-
-
58149102321
-
Molecular basis of metastasis
-
Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814-2823
-
(2008)
N Engl J Med
, vol.359
, pp. 2814-2823
-
-
Chiang, A.C.1
Massague, J.2
-
37
-
-
37649001973
-
ID genes mediate tumor reinitiation during breast cancer lung metastasis
-
Gupta GP, Perk J, Acharyya S et al (2007) ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 104:19506-19511
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 19506-19511
-
-
Gupta, G.P.1
Perk, J.2
Acharyya, S.3
-
38
-
-
44449084242
-
Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response
-
Swarbrick A, Roy E, Allen T et al (2008) Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 105:5402-5407
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 5402-5407
-
-
Swarbrick, A.1
Roy, E.2
Allen, T.3
-
39
-
-
28644432204
-
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
-
Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827
-
(2005)
Nature
, vol.438
, pp. 820-827
-
-
Kaplan, R.N.1
Riba, R.D.2
Zacharoulis, S.3
-
40
-
-
77949952457
-
Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development
-
Mihm MC Jr, Nelson JS (2010) Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol 37(Suppl 1):83-87
-
(2010)
J Cutan Pathol
, vol.37
, Issue.SUPPL. 1
, pp. 83-87
-
-
Mihm Jr., M.C.1
Nelson, J.S.2
-
41
-
-
33846239456
-
Beyond tumorigenesis: Cancer stem cells in metastasis
-
Li F, Tiede B, Massague J et al (2007) Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 17:3-14
-
(2007)
Cell Res
, vol.17
, pp. 3-14
-
-
Li, F.1
Tiede, B.2
Massague, J.3
-
43
-
-
0030967081
-
Chemokines induce migrational responses in human breast carcinoma cell lines
-
Youngs SJ, Ali SA, Taub DD et al (1997) Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71:257-266
-
(1997)
Int J Cancer
, vol.71
, pp. 257-266
-
-
Youngs, S.J.1
Ali, S.A.2
Taub, D.D.3
-
44
-
-
33745077057
-
Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy
-
Shu S, Cochran AJ, Huang RR et al (2006) Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy. Cancer Metastasis Rev 25:233-242
-
(2006)
Cancer Metastasis Rev
, vol.25
, pp. 233-242
-
-
Shu, S.1
Cochran, A.J.2
Huang, R.R.3
-
46
-
-
2542612840
-
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
-
Kawada K, Sonoshita M, Sakashita H et al (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64:4010-4017
-
(2004)
Cancer Res
, vol.64
, pp. 4010-4017
-
-
Kawada, K.1
Sonoshita, M.2
Sakashita, H.3
-
48
-
-
84862824075
-
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome
-
Hoshimoto S, Kuo CT, Chong KK et al (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Investig Dermatol 132: 1689-1697
-
(2012)
J Investig Dermatol
, vol.132
, pp. 1689-1697
-
-
Hoshimoto, S.1
Kuo, C.T.2
Chong, K.K.3
-
49
-
-
63449140854
-
CpG island methylator phenotype predicts progression of malignant melanoma
-
Tanemura A, Terando AM, Sim MS et al (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801-1807
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1801-1807
-
-
Tanemura, A.1
Terando, A.M.2
Sim, M.S.3
-
50
-
-
16444373352
-
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells
-
Mori T, Kim J, Yamano T et al (2005) Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65:1800-1807
-
(2005)
Cancer Res
, vol.65
, pp. 1800-1807
-
-
Mori, T.1
Kim, J.2
Yamano, T.3
-
51
-
-
33746159061
-
Estrogen receptoralpha methylation predicts melanoma progression
-
Mori T, Martinez SR, O'Day SJ et al (2006) Estrogen receptoralpha methylation predicts melanoma progression. Cancer Res 66:6692-6698
-
(2006)
Cancer Res
, vol.66
, pp. 6692-6698
-
-
Mori, T.1
Martinez, S.R.2
O'Day, S.J.3
-
52
-
-
74349098151
-
High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma
-
Goto Y, Arigami T, Murali R et al (2010) High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res 23:137-140
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, pp. 137-140
-
-
Goto, Y.1
Arigami, T.2
Murali, R.3
-
53
-
-
50349103346
-
Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes
-
Goto Y, Ferrone S, Arigami T et al (2008) Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 14:3401-3407
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3401-3407
-
-
Goto, Y.1
Ferrone, S.2
Arigami, T.3
-
54
-
-
2542522279
-
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
-
Hoon DS, Spugnardi M, Kuo C et al (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-4022
-
(2004)
Oncogene
, vol.23
, pp. 4014-4022
-
-
Hoon, D.S.1
Spugnardi, M.2
Kuo, C.3
-
55
-
-
65649092616
-
Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma
-
Kitago M, Martinez SR, Nakamura T et al (2009) Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 15:2988-2994
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2988-2994
-
-
Kitago, M.1
Martinez, S.R.2
Nakamura, T.3
-
56
-
-
79952421239
-
Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma
-
Nguyen T, Kuo C, Nicholl MB et al (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma. Epigenetics 6:388-394
-
(2011)
Epigenetics
, vol.6
, pp. 388-394
-
-
Nguyen, T.1
Kuo, C.2
Nicholl, M.B.3
-
57
-
-
44249087640
-
Quantitative analysis of methylation of genomic loci in earlystage rectal cancer predicts distant recurrence
-
de Maat MF, van de Velde CJ, van der Werff MP et al (2008) Quantitative analysis of methylation of genomic loci in earlystage rectal cancer predicts distant recurrence. J Clin Oncol 26: 2327-2335
-
(2008)
J Clin Oncol
, vol.26
, pp. 2327-2335
-
-
De Maat, M.F.1
Van De Velde, C.J.2
Van Der Werff, M.P.3
-
58
-
-
20944437231
-
The gene expression signatures of melanoma progression
-
Haqq C, Nosrati M, Sudilovsky D et al (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-6097
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 6092-6097
-
-
Haqq, C.1
Nosrati, M.2
Sudilovsky, D.3
-
59
-
-
65549107322
-
A multimarker assay to distinguish malignant melanomas from benign nevi
-
Kashani-Sabet M, Rangel J, Torabian S et al (2009) A multimarker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 106:6268-6272
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 6268-6272
-
-
Kashani-Sabet, M.1
Rangel, J.2
Torabian, S.3
-
60
-
-
72549092919
-
A multimarker prognostic assay for primary cutaneous melanoma
-
Kashani-Sabet M, Venna S, Nosrati M et al (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987-6992
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6987-6992
-
-
Kashani-Sabet, M.1
Venna, S.2
Nosrati, M.3
-
61
-
-
33750588921
-
Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma
-
Rangel J, Torabian S, Shaikh L et al (2006) Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24:4565-4569
-
(2006)
J Clin Oncol
, vol.24
, pp. 4565-4569
-
-
Rangel, J.1
Torabian, S.2
Shaikh, L.3
-
62
-
-
37449031252
-
Osteopontin as a molecular prognostic marker for melanoma
-
Rangel J, Nosrati M, Torabian S et al (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150
-
(2008)
Cancer
, vol.112
, pp. 144-150
-
-
Rangel, J.1
Nosrati, M.2
Torabian, S.3
-
63
-
-
49249129411
-
Novel role for RGS1 in melanoma progression
-
Rangel J, Nosrati M, Leong SP et al (2008) Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32:1207-1212
-
(2008)
Am J Surg Pathol
, vol.32
, pp. 1207-1212
-
-
Rangel, J.1
Nosrati, M.2
Leong, S.P.3
-
64
-
-
0016776479
-
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
-
Mastrangelo MJ, Bellet RE, Berkelhammer J et al (1975) Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36:1305-1308
-
(1975)
Cancer
, vol.36
, pp. 1305-1308
-
-
Mastrangelo, M.J.1
Bellet, R.E.2
Berkelhammer, J.3
-
65
-
-
1842582038
-
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group
-
Agarwala SS, Neuberg D, Park Y et al (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group. Cancer 100:1692-1698
-
(2004)
Cancer
, vol.100
, pp. 1692-1698
-
-
Agarwala, S.S.1
Neuberg, D.2
Park, Y.3
-
66
-
-
77952238515
-
A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma
-
Bedikian AY, Richards J, Kharkevitch D et al (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20:218-226
-
(2010)
Melanoma Res
, vol.20
, pp. 218-226
-
-
Bedikian, A.Y.1
Richards, J.2
Kharkevitch, D.3
-
67
-
-
73349133717
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
-
Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763-5771
-
(2009)
J Clin Oncol
, vol.27
, pp. 5763-5771
-
-
Senzer, N.N.1
Kaufman, H.L.2
Amatruda, T.3
-
68
-
-
56849112041
-
Chemoablation of metastatic melanoma using intralesional Rose Bengal
-
Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18:405-411
-
(2008)
Melanoma Res
, vol.18
, pp. 405-411
-
-
Thompson, J.F.1
Hersey, P.2
Wachter, E.3
-
69
-
-
49649115107
-
Therapy for unresectable recurrent and in-transit extremity melanoma
-
Gimbel MI, Delman KA, Zager JS (2008) Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 15:225-232
-
(2008)
Cancer Control
, vol.15
, pp. 225-232
-
-
Gimbel, M.I.1
Delman, K.A.2
Zager, J.S.3
-
70
-
-
48149092966
-
Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
-
Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195-2205
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 2195-2205
-
-
Beasley, G.M.1
Petersen, R.P.2
Yoo, J.3
-
71
-
-
0036210893
-
Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma
-
Lindner P, Doubrovsky A, Kam PC et al (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127-136
-
(2002)
Ann Surg Oncol
, vol.9
, pp. 127-136
-
-
Lindner, P.1
Doubrovsky, A.2
Kam, P.C.3
-
72
-
-
55149102005
-
Outcomes following isolated limb infusion for melanoma. A 14-year experience
-
Kroon HM, Moncrieff M, Kam PC et al (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15:3003-3013
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 3003-3013
-
-
Kroon, H.M.1
Moncrieff, M.2
Kam, P.C.3
-
73
-
-
33748968131
-
Hyperthermic regional perfusion for melanoma and sarcoma of the limbs
-
Fraker DL (1999) Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 36:841-907
-
(1999)
Curr Probl Surg
, vol.36
, pp. 841-907
-
-
Fraker, D.L.1
-
74
-
-
64949083543
-
A multiinstitutional experience of isolated limb infusion: Defining response and toxicity in the US
-
discussion 715-717
-
Beasley GM, Caudle A, Petersen RP et al (2009) A multiinstitutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 208:706-715; discussion 715-717
-
(2009)
J Am Coll Surg
, vol.208
, pp. 706-715
-
-
Beasley, G.M.1
Caudle, A.2
Petersen, R.P.3
-
75
-
-
68949207802
-
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis
-
Santillan AA, Delman KA, Beasley GM et al (2009) Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis. Ann Surg Oncol 16:2570-2578
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 2570-2578
-
-
Santillan, A.A.1
Delman, K.A.2
Beasley, G.M.3
-
76
-
-
0020365748
-
Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
-
Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910
-
(1982)
Eur J Cancer Clin Oncol
, vol.18
, pp. 905-910
-
-
Wieberdink, J.1
Benckhuysen, C.2
Braat, R.P.3
-
77
-
-
84862554871
-
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities
-
Chai CY, Deneve JL, Beasley GM et al (2012) A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 19:1637-1643
-
(2012)
Ann Surg Oncol
, vol.19
, pp. 1637-1643
-
-
Chai, C.Y.1
Deneve, J.L.2
Beasley, G.M.3
-
78
-
-
79952781372
-
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma
-
Beasley GM, Riboh JC, Augustine CK et al (2011) Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 29:1210-1215
-
(2011)
J Clin Oncol
, vol.29
, pp. 1210-1215
-
-
Beasley, G.M.1
Riboh, J.C.2
Augustine, C.K.3
-
79
-
-
77954572289
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
-
Augustine CK, Toshimitsu H, Jung SH et al (2010) Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 9:2090-2101
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2090-2101
-
-
Augustine, C.K.1
Toshimitsu, H.2
Jung, S.H.3
-
80
-
-
0028512070
-
Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study
-
Curley SA, Newman RA, Dougherty TB et al (1994) Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study. Ann Surg Oncol 1:389-399
-
(1994)
Ann Surg Oncol
, vol.1
, pp. 389-399
-
-
Curley, S.A.1
Newman, R.A.2
Dougherty, T.B.3
-
81
-
-
20644434717
-
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies
-
Pingpank JF, Libutti SK, Chang R et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465-3474
-
(2005)
J Clin Oncol
, vol.23
, pp. 3465-3474
-
-
Pingpank, J.F.1
Libutti, S.K.2
Chang, R.3
-
82
-
-
0346333288
-
Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver
-
Alexander HR Jr, Libutti SK, Pingpank JF et al (2003) Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9: 6343-6349
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6343-6349
-
-
Alexander Jr., H.R.1
Libutti, S.K.2
Pingpank, J.F.3
-
83
-
-
79954601182
-
A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma
-
June 2010
-
Pingpank JF, Hughes MS, Alexander HR et al (2010) A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. In: Presented at the American Society of Clinical Oncology, June 2010
-
(2010)
Presented at the American Society of Clinical Oncology
-
-
Pingpank, J.F.1
Hughes, M.S.2
Alexander, H.R.3
-
84
-
-
84873081713
-
Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients with melanoma liver metastases-Efficacy update of the phase 3 trial (NCT00324727
-
Stockholm, Sweden, Sept 2011
-
Pingpank JF, Hughes M, Alexander HR et al (2011) Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients with melanoma liver metastases-efficacy update of the phase 3 trial (NCT00324727). In: European Multidisciplinary Cancer Congress. Stockholm, Sweden, Sept 2011
-
(2011)
European Multidisciplinary Cancer Congress
-
-
Pingpank, J.F.1
Hughes, M.2
Alexander, H.R.3
-
85
-
-
84868213257
-
Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients (pts) with melanoma liver metastases: Updated data from the phase III trial
-
Zager JS, JF. P (2011) Percutaneous hepatic perfusion (PHP) vs. best alternative care (BAC) for patients (pts) with melanoma liver metastases: Updated data from the phase III trial. In: International Melanoma Centers Meeting, Tampa, Florida. Pigment Cell Melanoma Res 24:1010-1011
-
(2011)
International Melanoma Centers Meeting, Tampa, Florida. Pigment Cell Melanoma Res
, vol.24
, pp. 1010-1011
-
-
Zager, J.S.1
Jf, P.2
-
86
-
-
0035880957
-
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
-
Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634
-
(2001)
J Clin Oncol
, vol.19
, pp. 3622-3634
-
-
Balch, C.M.1
Soong, S.J.2
Gershenwald, J.E.3
-
87
-
-
33749618081
-
Clinical relevance of melanoma micrometastases (?0.1 mm) in sentinel nodes: Are these nodes to be considered negative?
-
van Akkooi AC, de Wilt JH, Verhoef C et al (2006) Clinical relevance of melanoma micrometastases (?0.1 mm) in sentinel nodes: Are these nodes to be considered negative? Ann Oncol 17:1578-1585
-
(2006)
Ann Oncol
, vol.17
, pp. 1578-1585
-
-
Van Akkooi, A.C.1
De Wilt, J.H.2
Verhoef, C.3
-
88
-
-
58149375115
-
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes
-
van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248:949-955
-
(2008)
Ann Surg
, vol.248
, pp. 949-955
-
-
Van Akkooi, A.C.1
Nowecki, Z.I.2
Voit, C.3
-
89
-
-
0030966641
-
Optimal selective sentinel lymph node dissection in primary malignant melanoma
-
discussion 673
-
Leong SP, Steinmetz I, Habib FA et al (1997) Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 132:666-672; discussion 673
-
(1997)
Arch Surg
, vol.132
, pp. 666-672
-
-
Leong, S.P.1
Steinmetz, I.2
Habib, F.A.3
-
90
-
-
3843119131
-
Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma
-
Leong SP (2004) Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma. Curr Treat Options Oncol 5:185-194
-
(2004)
Curr Treat Options Oncol
, vol.5
, pp. 185-194
-
-
Leong, S.P.1
-
91
-
-
0036895061
-
Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy
-
Ranieri JM, Wagner JD, Azuaje R et al (2002) Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9:975-981
-
(2002)
Ann Surg Oncol
, vol.9
, pp. 975-981
-
-
Ranieri, J.M.1
Wagner, J.D.2
Azuaje, R.3
-
92
-
-
0041784818
-
The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance?
-
Carlson GW, Murray DR, Lyles RH et al (2003) The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? Ann Surg Oncol 10:575-581
-
(2003)
Ann Surg Oncol
, vol.10
, pp. 575-581
-
-
Carlson, G.W.1
Murray, D.R.2
Lyles, R.H.3
-
93
-
-
0037269753
-
Prediction of nonsentinel lymph node status in melanoma
-
Reeves ME, Delgado R, Busam KJ et al (2003) Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10:27-31
-
(2003)
Ann Surg Oncol
, vol.10
, pp. 27-31
-
-
Reeves, M.E.1
Delgado, R.2
Busam, K.J.3
-
94
-
-
4644309225
-
Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma
-
Lee JH, Essner R, Torisu-Itakura H et al (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma. J Clin Oncol 22:3677-3684
-
(2004)
J Clin Oncol
, vol.22
, pp. 3677-3684
-
-
Lee, J.H.1
Essner, R.2
Torisu-Itakura, H.3
-
95
-
-
4644260554
-
Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma
-
Scolyer RA, Li LX, McCarthy SW et al (2004) Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 122:532-539
-
(2004)
Am J Clin Pathol
, vol.122
, pp. 532-539
-
-
Scolyer, R.A.1
Li, L.X.2
McCarthy, S.W.3
-
96
-
-
20544433657
-
Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma
-
Sabel MS, Griffith K, Sondak VK et al (2005) Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201:37-47
-
(2005)
J Am Coll Surg
, vol.201
, pp. 37-47
-
-
Sabel, M.S.1
Griffith, K.2
Sondak, V.K.3
-
97
-
-
34250679266
-
Sentinel lymph node biopsy in melanoma: A micromorphometric study relating to prognosis and completion lymph node dissection
-
Debarbieux S, Duru G, Dalle S et al (2007) Sentinel lymph node biopsy in melanoma: A micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 157:58-67
-
(2007)
Br J Dermatol
, vol.157
, pp. 58-67
-
-
Debarbieux, S.1
Duru, G.2
Dalle, S.3
-
98
-
-
34648817394
-
Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma
-
Scheri RP, Essner R, Turner RR et al (2007) Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14:2861-2866
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 2861-2866
-
-
Scheri, R.P.1
Essner, R.2
Turner, R.R.3
-
99
-
-
34548537468
-
Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma
-
discussion 678-679
-
Page AJ, Carlson GW, Delman KA et al (2007) Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg 73:674-678; discussion 678-679
-
(2007)
Am Surg
, vol.73
, pp. 674-678
-
-
Page, A.J.1
Carlson, G.W.2
Delman, K.A.3
-
100
-
-
47149097293
-
Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients
-
Glumac N, Hocevar M, Zadnik V et al (2008) Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol 98:46-48
-
(2008)
J Surg Oncol
, vol.98
, pp. 46-48
-
-
Glumac, N.1
Hocevar, M.2
Zadnik, V.3
-
101
-
-
50049128948
-
Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node
-
Rossi CR, De Salvo GL, Bonandini E et al (2008) Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 15:1202-1210
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 1202-1210
-
-
Rossi, C.R.1
De Salvo, G.L.2
Bonandini, E.3
-
102
-
-
50049112105
-
Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
-
Frankel TL, Griffith KA, Lowe L et al (2008) Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 15:2403-2411
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 2403-2411
-
-
Frankel, T.L.1
Griffith, K.A.2
Lowe, L.3
-
103
-
-
44949097220
-
The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-A retrospective analysis of 392 cases
-
Guggenheim M, Dummer R, Jung FJ et al (2008) The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-a retrospective analysis of 392 cases. Br J Cancer 98:1922-1928
-
(2008)
Br J Cancer
, vol.98
, pp. 1922-1928
-
-
Guggenheim, M.1
Dummer, R.2
Jung, F.J.3
-
104
-
-
52049107850
-
Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma
-
Gershenwald JE, Andtbacka RH, Prieto VG et al (2008) Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26:4296-4303
-
(2008)
J Clin Oncol
, vol.26
, pp. 4296-4303
-
-
Gershenwald, J.E.1
Andtbacka, R.H.2
Prieto, V.G.3
-
105
-
-
68949086788
-
Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node
-
van der Ploeg IM, Kroon BB, Antonini N et al (2009) Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg 250: 301-304
-
(2009)
Ann Surg
, vol.250
, pp. 301-304
-
-
Van Der Ploeg, I.M.1
Kroon, B.B.2
Antonini, N.3
-
106
-
-
77952099173
-
Influence of sentinel lymph node tumor burden on survival in melanoma
-
Francischetto T, Spector N, Neto Rezende JF et al (2010) Influence of sentinel lymph node tumor burden on survival in melanoma. Ann Surg Oncol 17:1152-1158
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 1152-1158
-
-
Francischetto, T.1
Spector, N.2
Neto Rezende, J.F.3
-
107
-
-
34547631945
-
Prognostic significance of isolated HMB45 or Melan A positive cells in melanoma sentinel lymph nodes
-
Satzger I, Volker B, Meier A et al (2007) Prognostic significance of isolated HMB45 or Melan A positive cells in melanoma sentinel lymph nodes. Am J Surg Pathol 31:1175-1180
-
(2007)
Am J Surg Pathol
, vol.31
, pp. 1175-1180
-
-
Satzger, I.1
Volker, B.2
Meier, A.3
-
108
-
-
82955237235
-
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database
-
White RL Jr, Ayers GD, Stell VH et al (2011) Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 18:3593-3600
-
(2011)
Ann Surg Oncol
, vol.18
, pp. 3593-3600
-
-
White Jr., R.L.1
Ayers, G.D.2
Stell, V.H.3
-
109
-
-
4344630988
-
The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement
-
Dewar DJ, Newell B, Green MA et al (2004) The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 22: 3345-3349
-
(2004)
J Clin Oncol
, vol.22
, pp. 3345-3349
-
-
Dewar, D.J.1
Newell, B.2
Green, M.A.3
-
110
-
-
0031970288
-
Primary therapy of malignant melanomas: Sentinel lymphadenectomy
-
Bachter D, Balda BR, Vogt H et al (1998) Primary therapy of malignant melanomas: Sentinel lymphadenectomy. Int J Dermatol 37:278-282
-
(1998)
Int J Dermatol
, vol.37
, pp. 278-282
-
-
Bachter, D.1
Balda, B.R.2
Vogt, H.3
-
111
-
-
0030930407
-
Sentinel node biopsy in melanoma patients: Dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance
-
discussion 793
-
Pijpers R, Borgstein PJ, Meijer S et al (1997) Sentinel node biopsy in melanoma patients: Dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 21:788-792; discussion 793
-
(1997)
World J Surg
, vol.21
, pp. 788-792
-
-
Pijpers, R.1
Borgstein, P.J.2
Meijer, S.3
-
112
-
-
0030753746
-
Sentinel lymph node evaluation in melanoma
-
Brady MS, Coit DG (1997) Sentinel lymph node evaluation in melanoma. Arch Dermatol 133:1014-1020
-
(1997)
Arch Dermatol
, vol.133
, pp. 1014-1020
-
-
Brady, M.S.1
Coit, D.G.2
-
113
-
-
0028052025
-
The orderly progression of melanoma nodal metastases
-
Reintgen D, Cruse CW, Wells K et al (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220:759-767
-
(1994)
Ann Surg
, vol.220
, pp. 759-767
-
-
Reintgen, D.1
Cruse, C.W.2
Wells, K.3
-
114
-
-
0028788777
-
The role of selective lymphadenectomy in the management of patients with malignant melanoma
-
Glass LF, Fenske NA, Messina JL et al (1995) The role of selective lymphadenectomy in the management of patients with malignant melanoma. Dermatol Surg 21:979-983
-
(1995)
Dermatol Surg
, vol.21
, pp. 979-983
-
-
Glass, L.F.1
Fenske, N.A.2
Messina, J.L.3
-
115
-
-
0029074162
-
Minimal-access surgery for staging of malignant melanoma
-
discussion 659-660
-
Krag DN, Meijer SJ, Weaver DL et al (1995) Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-658; discussion 659-660
-
(1995)
Arch Surg
, vol.130
, pp. 654-658
-
-
Krag, D.N.1
Meijer, S.J.2
Weaver, D.L.3
-
116
-
-
0029038818
-
Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes
-
Thompson JF, McCarthy WH, Bosch CM et al (1995) Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5:255-260
-
(1995)
Melanoma Res
, vol.5
, pp. 255-260
-
-
Thompson, J.F.1
McCarthy, W.H.2
Bosch, C.M.3
-
117
-
-
0032897292
-
Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients
-
Lenisa L, Santinami M, Belli F et al (1999) Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients. J Exp Clin Cancer Res 18:69-74
-
(1999)
J Exp Clin Cancer Res
, vol.18
, pp. 69-74
-
-
Lenisa, L.1
Santinami, M.2
Belli, F.3
-
118
-
-
0034662008
-
Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma
-
Wagner JD, Gordon MS, Chuang TY et al (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462
-
(2000)
Cancer
, vol.89
, pp. 453-462
-
-
Wagner, J.D.1
Gordon, M.S.2
Chuang, T.Y.3
-
119
-
-
0035371058
-
A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma
-
Starz H, Balda BR, Kramer KU et al (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110-2121
-
(2001)
Cancer
, vol.91
, pp. 2110-2121
-
-
Starz, H.1
Balda, B.R.2
Kramer, K.U.3
-
120
-
-
2942633520
-
Sentinel lymphonodectomy and s-classification: A successful strategy for better prediction and improvement of outcome of melanoma
-
Starz H, Siedlecki K, Balda BR (2004) Sentinel lymphonodectomy and s-classification: A successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11:162S-168S
-
(2004)
Ann Surg Oncol
, vol.11
-
-
Starz, H.1
Siedlecki, K.2
Balda, B.R.3
-
121
-
-
79957970164
-
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria
-
van der Ploeg AP, van Akkooi AC, Rutkowski P et al (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206-2214
-
(2011)
J Clin Oncol
, vol.29
, pp. 2206-2214
-
-
Van Der Ploeg, A.P.1
Van Akkooi, A.C.2
Rutkowski, P.3
-
122
-
-
2942640198
-
Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience
-
Leong SP (2004) Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 11:192S-197S
-
(2004)
Ann Surg Oncol
, vol.11
-
-
Leong, S.P.1
-
123
-
-
84862268896
-
The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival
-
Baehner FL, Li R, Jenkins T et al (2012) The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 19:1034-1042
-
(2012)
Ann Surg Oncol
, vol.19
, pp. 1034-1042
-
-
Baehner, F.L.1
Li, R.2
Jenkins, T.3
-
124
-
-
0028150831
-
Karnofsky Memorial Lecture. Natural history of small breast cancers
-
Hellman S (1994) Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12:2229-2234
-
(1994)
J Clin Oncol
, vol.12
, pp. 2229-2234
-
-
Hellman, S.1
-
125
-
-
33749053823
-
Sentinelnode biopsy or nodal observation in melanoma
-
Morton DL, Thompson JF, Cochran AJ et al (2006) Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317
-
(2006)
N Engl J Med
, vol.355
, pp. 1307-1317
-
-
Morton, D.L.1
Thompson, J.F.2
Cochran, A.J.3
-
126
-
-
34548670729
-
The role of sentinel lymph node biopsy in the management of melanoma
-
Amersi F, Morton DL (2007) The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 41:241-256
-
(2007)
Adv Surg
, vol.41
, pp. 241-256
-
-
Amersi, F.1
Morton, D.L.2
-
127
-
-
84655168007
-
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
-
Eggermont AM, Suciu S, Testori A et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225
-
(2012)
Eur J Cancer
, vol.48
, pp. 218-225
-
-
Eggermont, A.M.1
Suciu, S.2
Testori, A.3
-
128
-
-
0347503603
-
Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials
-
Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
-
(2003)
Lancet Oncol
, vol.4
, pp. 748-759
-
-
Eigentler, T.K.1
Caroli, U.M.2
Radny, P.3
-
129
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
-
(2005)
N Engl J Med
, vol.353
, pp. 2135-2147
-
-
Curtin, J.A.1
Fridlyand, J.2
Kageshita, T.3
-
130
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
131
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
132
-
-
84862732834
-
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations
-
Greger JG, Eastman SD, Zhang V et al (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-920
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 909-920
-
-
Greger, J.G.1
Eastman, S.D.2
Zhang, V.3
-
133
-
-
79960708519
-
Phase II, open-label, singlearm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
-
Guo J, Si L, Kong Y et al (2011) Phase II, open-label, singlearm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-2909
-
(2011)
J Clin Oncol
, vol.29
, pp. 2904-2909
-
-
Guo, J.1
Si, L.2
Kong, Y.3
-
134
-
-
84862908265
-
BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma
-
Kim KB, Sosman JA, Fruehauf JP et al (2012) BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30: 34-41
-
(2012)
J Clin Oncol
, vol.30
, pp. 34-41
-
-
Kim, K.B.1
Sosman, J.A.2
Fruehauf, J.P.3
-
135
-
-
80052536175
-
New drugs in melanoma: It's a whole new world
-
Eggermont AM, Robert C (2011) New drugs in melanoma: It's a whole new world. Eur J Cancer 47:2150-2157
-
(2011)
Eur J Cancer
, vol.47
, pp. 2150-2157
-
-
Eggermont, A.M.1
Robert, C.2
-
136
-
-
0016176253
-
BCG immunotherapy of malignant melanoma: Summary of a seven-year experience
-
Morton DL, Eilber FR, Holmes EC et al (1974) BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643
-
(1974)
Ann Surg
, vol.180
, pp. 635-643
-
-
Morton, D.L.1
Eilber, F.R.2
Holmes, E.C.3
-
137
-
-
77957723967
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8? T cell dysfunction in melanoma patients
-
Fourcade J, Sun Z, Benallaoua M et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8? T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186
-
(2010)
J Exp Med
, vol.207
, pp. 2175-2186
-
-
Fourcade, J.1
Sun, Z.2
Benallaoua, M.3
-
138
-
-
79953859155
-
Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients
-
Leong SP, Zuber M, Ferris RL et al (2011) Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. J Surg Oncol 103:518-530
-
(2011)
J Surg Oncol
, vol.103
, pp. 518-530
-
-
Leong, S.P.1
Zuber, M.2
Ferris, R.L.3
-
139
-
-
77954058743
-
Chemotherapy resistance abrogation in metastatic melanoma
-
Tawbi HA, Buch SC (2010) Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 8: 259-266
-
(2010)
Clin Adv Hematol Oncol
, vol.8
, pp. 259-266
-
-
Tawbi, H.A.1
Buch, S.C.2
-
140
-
-
58149396712
-
Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694
-
Tarhini AA, Stuckert J, Lee S et al (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27:38-44
-
(2009)
J Clin Oncol
, vol.27
, pp. 38-44
-
-
Tarhini, A.A.1
Stuckert, J.2
Lee, S.3
-
141
-
-
77957331901
-
Correlation of molecular human leukocyte antigen typing and outcome in highrisk melanoma patients receiving adjuvant interferon
-
Gogas H, Kirkwood JM, Falk CS et al (2010) Correlation of molecular human leukocyte antigen typing and outcome in highrisk melanoma patients receiving adjuvant interferon. Cancer 116:4326-4333
-
(2010)
Cancer
, vol.116
, pp. 4326-4333
-
-
Gogas, H.1
Kirkwood, J.M.2
Falk, C.S.3
-
142
-
-
32644454916
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon
-
Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718
-
(2006)
N Engl J Med
, vol.354
, pp. 709-718
-
-
Gogas, H.1
Ioannovich, J.2
Dafni, U.3
-
143
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
144
-
-
79960403316
-
Cytotoxic T-lymphocyte-associated antigen-4
-
Salama AK, Hodi FS (2011) Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 17:4622-4628
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4622-4628
-
-
Salama, A.K.1
Hodi, F.S.2
-
145
-
-
0023888654
-
Hypothyroidism after treatment with interleukin-2 and lymphokineactivated killer cells
-
Atkins MB, Mier JW, Parkinson DR et al (1988) Hypothyroidism after treatment with interleukin-2 and lymphokineactivated killer cells. N Engl J Med 318:1557-1563
-
(1988)
N Engl J Med
, vol.318
, pp. 1557-1563
-
-
Atkins, M.B.1
Mier, J.W.2
Parkinson, D.R.3
-
146
-
-
34247868145
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
-
Yurkovetsky ZR, Kirkwood JM, Edington HD et al (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13:2422-2428
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2422-2428
-
-
Yurkovetsky, Z.R.1
Kirkwood, J.M.2
Edington, H.D.3
-
147
-
-
33745989541
-
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
-
Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171
-
(2006)
J Clin Oncol
, vol.24
, pp. 3164-3171
-
-
Moschos, S.J.1
Edington, H.D.2
Land, S.R.3
-
148
-
-
33947423447
-
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b
-
Wang W, Edington HD, Rao UN et al (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1523-1531
-
-
Wang, W.1
Edington, H.D.2
Rao, U.N.3
-
149
-
-
84861083983
-
Dabrafenib in patients with melanoma untreated brain metastases and other solid tumours: A phase 1 dose-escalation trial
-
Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
150
-
-
84873098095
-
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring
-
Abstr 8533
-
Tarhini AA, Edington H, Butterfield LH et al (2012) Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring. Proceedings. J Clin Oncol 30:Abstr 8533
-
(2012)
Proceedings. J Clin Oncol
, vol.30
-
-
Tarhini, A.A.1
Edington, H.2
Butterfield, L.H.3
-
151
-
-
84856069688
-
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
-
Tarhini AA, Cherian J, Moschos SJ et al (2012) Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30:322-328
-
(2012)
J Clin Oncol
, vol.30
, pp. 322-328
-
-
Tarhini, A.A.1
Cherian, J.2
Moschos, S.J.3
|